---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-022615"
form_type: "8-K/A"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:24:54.991120+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Icotrokinra shows positive Phase 2b UC (corrected p-value) and Phase 3 PsO top-line data

## Summary
- Phase 2b ANTHEM-UC: highest dose achieved 63.5% clinical response and 30.2% clinical remission at Wk12 vs 27.0% and 11.1% placebo; p-values corrected to <0.001 and <0.01.
- Phase 3 ICONIC-LEAD: 65% IGA 0/1 and 50% PASI 90 at Wk16; at Wk24: 74% IGA 0/1, 65% PASI 90; 46% completely clear skin.
- Phase 3 ICONIC-ADVANCE 1&2: met co-primary endpoints vs placebo; superior to deucravacitinib on all key secondary endpoints at Wk16 and Wk24.
- Initiation of ICONIC-ASCEND: first head-to-head study of oral icotrokinra vs injectable biologic (ustekinumab) in moderate-to-severe PsO.

## SEC filing metadata
- accession: 0001104659-25-022615
- form_type: 8-K/A
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925022615/0001104659-25-022615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925022615/tm258886d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-022615
- JSON: https://secwatch.observer/filing/0001104659-25-022615.json
- Plain text: https://secwatch.observer/filing/0001104659-25-022615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.